NAPROXEN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

NAPROXEN SODIUM

Saadav alates:

DOMINION PHARMACAL

ATC kood:

M01AE02

INN (Rahvusvaheline Nimetus):

NAPROXEN

Annus:

220MG

Ravimvorm:

TABLET

Koostis:

NAPROXEN SODIUM 220MG

Manustamisviis:

ORAL

Ühikuid pakis:

24/100/125

Retsepti tüüp:

OTC

Terapeutiline ala:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113934003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2020-05-06

Toote omadused

PRODUCT MONOGRAPH
NAPROXEN
Naproxen Sodium Tablets USP
220 mg
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Québec
H4P 2T4
www.pharmascience.com DATE OF REVISION:
May 10, 2019
Submission Control no.: 227094
_ _
_NAPROXEN Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
......................................................................................................
6
DRUG INTERACTIONS
......................................................................................................
9
DOSAGE AND ADMINISTRATION
................................................................................
11
OVERDOSAGE
...................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 12
STORAGE AND STABILITY
............................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 14
PART II: SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
............................................................................
15
CLINICAL TRIALS
..................